This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells.
This research study involves the study drugs:
* CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Voluntarily sign informed consent form(s)
≥18 years of age at the time of signing informed consent
Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Karnofsky ≥60%, see Appendix A)
Follicular Lymphoma (FL) grade 1, grade 2, or grade 3a
Treatment with an any investigational cellular therapy within 8 weeks prior to apheresis.
Any systemic anti-cancer therapy within 1 weeks or 5 half-lives of leukapheresis, whichever is shortest, excluding steroids (prednisone) at or below physiologic dosing (5mg).
No bispecific T cell engagers within 6 months of leukapheresis.
No bendamustime within 6 months of leukapheresis.
Marcela V. Maus, M.D.,Ph.D.
Lead sponsor
Massachusetts General Hospital
Sponsor institution